Compare Gap Inc (GAP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Incyte Corporation — how do they compare? Gap Inc trades at $23.23 (market cap $8.21B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 2.8× Gap Inc's market cap, and Gap Inc pays a 3% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Incyte Corporation for 33 Days on average.
| GAP | INCY | |
|---|---|---|
Market Cap | $8.21B | $22.85B |
Volume | 5,192,917 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $129.93 |
52-Week Low | $18.35 | $83.80 |
Typical Hold Time | 37 Days | 33 Days |
Enterprise Value | $11.44B | $18.35B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.36, down 1.06% on the day, with a bullish technical signal supported by moving averages. The company shows strong profitability with a 43.26% gross margin and 33.78% ROE, while valuation ratios like a P/E of 7.04 and P/S of 0.58 suggest potential undervaluation. Recent earnings beats in Q1 and Q2 2026 and a new 'fashiontainment' partnership with boy band JYT highlight operational momentum.
The outlook is positive given earnings growth and low valuation, but risks include reliance on Old Navy's turnaround and competitive pressures. Analyst consensus is a $25.67 price target with a 'Hold' bias, indicating modest upside from current levels amid mixed institutional sentiment.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
